Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Source: SeekingAlpha
2025-12-15 11:59:45 ET
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment December 15, 2025 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
Milestone Pharmaceuticals Inc. (MIST) Discusses FDA Approval and Clinical Insights for CARDAMYST Nasal Spray in PSVT Treatment Transcript
Milestone Pharmaceuticals Inc.
NASDAQ: MIST
MIST Trading
1.16% G/L:
$1.745 Last:
672,931 Volume:
$1.77 Open:
MIST Latest News
March 12, 2026 08:00:00 am
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
MIST Stock Data
$157,137,440
68,561,322
0.37%
48
N/A
Biotechnology & Life Sciences
Healthcare
CA
Montral
